Lead Sponsor

Pfizer

Age

40 - 80 years

Sex

ALL

Healthy Volunteers

No

•Male or female subjects between, and including, the ages of 40 and 80 years.
•Subjects with a diagnosis, for at least 6 months, of moderate to severe COPD (GOLD) and who meet the criteria for Stage II-III disease, subjects must have had stable disease for at least 1 month prior to screening.
•Subjects must have a smoking history of at least 10 pack-years and be current smokers or ex-smokers that gave up \> 6 months ago.

•More than 2 exacerbations of COPD requiring treatment with oral steroids in the preceding year or hospitalization for the treatment of COPD within 3 months of screening or more than twice during the preceding year.
•History or presence of significant cardiovascular disease.
•ECG abnormalities.
•Significant concomitant clinical disease that could interfere with the conduct, safety or interpretation of results of this study.
•Evidence of organ or blood disorders.

Related studies

NCT07665931 · Chronic Obstructive Pulmonary Disease (COPD), Pulmonary Hyperinflation

NCT07646587 · COPD (Chronic Obstructive Pulmonary Disease)

NCT05743582 · Chronic Obstructive Pulmonary Disease

NCT07190222 · Chronic Obstructive Pulmonary Disease

NCT07047092 · Chronic Obstructive Pulmonary Disease Exacerbation, Obstructive Sleep Apnea Exacerbation

A Phase II, Study To Evaluate The Efficacy And Safety Of PH-797804 In Adults With Moderate To Severe Chronic Obstructive Pulmonary Disease (COPD).